Lana Pine

Aspartyl-alanyl-diketopiperazine (Ampion), an intra-articular injection, works to regulate immune responses that are connected to pain, inflammation, and joint damage in patients with osteoarthritis of the knee.

In rheumatoid arthritis, a treat-to-target approach aims for remission or low disease activity within the first 3 months. However, investigators noted that improvements continued to increase throughout the 52-week period.

Rheumatology Network interviewed Jeffrey Stark, MD, to discuss the BE COMPLETE study, which examined the efficacy of bimekizumab for treating psoriatic arthritis.

The long-term success of any psoriatic arthritis treatment may be predictable as early as 3 months if a timely assessment and adjustment of disease management is prioritized.

“This dramatic change in healthcare delivery led to significant challenges amongst healthcare management teams, healthcare professionals as well as patients, especially during the early phases of implementation," investigators stated.

Results indicated that a brief methotrexate withdrawal after COVID-19 vaccine doses may improve immunogenicity in patients with rheumatoid arthritis.

Take 5 minutes to catch up on Rheumatology Network's highlights from the week ending February 25, 2021.

Uma Mahadevan, MD, gives Rheumatology Network an overview of her Rheumatology Winter Clinical Symposium presentation, “Gastroenterology Update for the Rheumatologist.”

Anisha Dua, MD, MPH, discusses the mimics, related conditions, and new diseases in the field of vasculitis as it relates to rheumatology.

On this month's episode of Overdrive, Rheumatology Network interviewed Terence Rooney, MD, to discuss the findings of a network meta-analysis that examined the efficacy of guselkumab (TREMFYA) for skin clearance and joint improvements in patients with psoriatic arthritis.

Susan Shenoi, MBBS, MS, discusses the recent developments in pediatric rheumatology as well as new therapies and guidelines for treating juvenile idiopathic arthritis.

Roy Fleishmann, MD, discusses his Rheumatology Winter Clinical Symposium presentation, “Beyond the package insert: JAK inhibitors (jakinibs): safety issues.”

Take 5 minutes to catch up on Rheumatology Network's highlights from the week ending February 18, 2021.

Arthur Kavanaugh, MD, provides a year in review, including new developments, in rheumatoid arthritis as well as his thoughts on the use of biosimilars.

Roy Fleishmann, MD, discusses his Rheumatology Winter Clinical Symposium presentation, “SLE Update: Novel treatments, and how we assess them.”

Arthur Kavanaugh, MD, explains the recent developments in psoriatic arthritis and spondyloarthritis, as well as what rheumatologists should look forward to in 2022.

Arthur Kavanaugh, MD, discusses the Rheumatology Winter Clinical Symposium, which runs from February 16 – 19.

Take 5 minutes to catch up on Rheumatology Network's highlights from the week ending February 11, 2021.

According to the study, weight loss may be an effective strategy to prevent or treat pain in patients with hand osteoarthritis.

“Food insecurity may increase an individual’s dependence on inexpensive energy-dense foods that lead to the development of chronic diseases that may affect mental health," investigators stated.

Upadacitinib monotherapy was effective in inhibiting structural joint damage progression in patients with rheumatoid arthritis who were MTX-naïve or had an inadequate response to MTX.

Rheumatology Network interviewed Terence Rooney, MD, to discuss the findings of a Network Meta-Analysis that examined the efficacy of guselkumab (TREMFYA) for skin clearance and joint improvements in patients with psoriatic arthritis.

Given the recent concerns regarding venous thromboembolic events in patients with rheumatic disease and pre-existing cardiovascular risk factors being treated with tofacitinib, investigators addressed the occurrence of VTE in patients with PsA.

The American College of Rheumatology (ACR) has published guidance regarding COVID-19 vaccination for patients with rheumatic diseases, with emphasis placed on supplemental and booster doses for patients with rheumatic disease.

Take 5 minutes to catch up on Rheumatology Network's highlights from the week ending February 4, 2021.

Xavier Mariette, MD, PhD, explains the results of his study examining how rituximab impacts B-cell and T-cell response to COVID-19 vaccine in patients with rheumatic disease.

Mary Wheatley, IOM, CAE, discusses the National Scleroderma Foundation, its recent name change, and the importance of raising awareness of this rare rheumatic condition.

While subclinical synovitis is a common problem in the prognosis of RA, it is difficult to detect it by imaging methods and leads to joint destruction in some patients.

As telehealth is an emerging and rapidly changing form of pediatric rheumatology care, engaging patients, caregivers, and rheumatologists will help streamline care to improve satisfaction and overall experience.

"Prevention of severe radiographic progression in a certain percentage of patients remains a challenge because of inadequate treatment response or adverse events associated with therapeutic agents," investigators stated.